Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6950425 | 0.99 | ALOX15 (0.45) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| SCHEMBL14595479 | 0.94 | OPRM1 (0.43) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| SCHEMBL14595476 | 0.94 | OPRM1 (0.48) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| SCHEMBL8740612 | 0.91 | OPRM1 (0.41) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL8740646 | 0.90 | OPRM1 (0.40) | ALOX15OPRM1OPRL1 | |
| Hydrochloric Acid SCHEMBL9355945 | 0.90 | ALOX15 (0.54) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| SCHEMBL14595478 | 0.89 | OPRM1 (0.46) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| SCHEMBL8677685 | 0.88 | ALOX15 (0.48) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| Atiprimod SCHEMBL93890 | 0.87 | OPRM1 (0.41) | ALOX15OPRM1OPRL1DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL9355990 | 0.87 | ALOX15 (0.47) | ALOX15OPRM1OPRL1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010014676-A1 | Immunosuppressive compositions | BADGER ALISON MARY (US) | 2001-08-16 | — | — | US | claimed |
| US-6051596-A | COADMINISTRATION OF NON-SPECIFIC SUPPRESSOR CELL INDUCING COMPOUND COMPRISES N,N-DIMETHYL-8,8-DIPROPYL-2-AZASPIRO(4,5)DECANE-2-PROPANAMINE IN COMBINATION WITH CYCLOSPORIN A | ANORMED, INC. (CA) | 2000-04-18 | — | — | US | claimed |
| EP-0572537-B1 | CYTOKINE INHIBITORS | ANORMED INC (CA) | 1999-11-17 | — | — | EP | claimed |
| US-5981538-A | SKIN DISORDERS | ANORMED INC. (CA) | 1999-11-09 | — | — | US | claimed |
| US-5900430-A | USING AN AZASPIRANE COMPOUND | ANORMED, INC. (CA) | 1999-05-04 | — | — | US | claimed |
| EP-0542860-B1 | IMMUNOSUPPRESSIVE COMPOSITIONS | ANORMED INC (CA) | 1998-05-20 | — | — | EP | claimed |
| EP-0837678-A1 | N,N-DIMETHYL-8,8-DIPROPYL-2-AZASPIRO 4,5]DECANE-2-PROPANAMINE DIMALEATE | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-29 | — | — | EP | claimed |
| EP-0837678-A4 | — | — | 1998-04-29 | — | — | EP | claimed |
| EP-0654996-A4 | METHODS OF TREATING PSORIASIS EMPLOYING SUBSTITUTED AZASPIRANES. | SMITHKLINE BEECHAM CORP (US) | 1997-09-17 | — | — | EP | claimed |
| WO-1997002820-A1 | N,N-DIMETHYL-8,8-DIPROPYL-2-AZASPIRO[4,5]DECANE-2-PROPANAMINE DIMALEATE | ANORMED INC. (CA) | 1997-01-30 | — | — | WO | claimed |
| US-5395848-A | Administering anticholesterol agent to mammals; atherosclerosis | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-07 | — | — | US | claimed |
| EP-0609358-A4 | METHODS FOR TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES. | SMITHKLINE BEECHAM CORP (US) | 1994-10-12 | — | — | EP | claimed |
| EP-0609358-A1 | METHODS FOR TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-08-10 | — | — | EP | claimed |
| WO-1994004150-A1 | METHODS OF TREATING PSORIASIS EMPLOYING SUBSTITUTED AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-03 | — | — | WO | claimed |
| EP-0572537-A1 | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-12-08 | — | — | EP | claimed |
| EP-0572537-A4 | CYTOKINE INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1993-10-14 | — | — | EP | claimed |
| EP-0542860-A1 | IMMUNOSUPPRESSIVE COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-05-26 | — | — | EP | claimed |
| WO-1993007869-A1 | METHODS FOR TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1992014462-A1 | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-09-03 | — | — | WO | claimed |
| WO-1992002229-A1 | IMMUNOSUPPRESSIVE COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-02-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014676-A1 | Immunosuppressive compositions | NFATC1, CD47, ICOS | ALOX15 368/4885OPRM1 3246/4885OPRL1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.